Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic

Jue SHI, Timothy J. Mitchison

Research output: Contribution to journalReview articlepeer-review

33 Citations (Scopus)

Abstract

Anti-mitotic cancer drugs include classic microtubule-targeting drugs, such as taxanes and vinca alkaloids, and the newer spindle-targeting drugs, such as inhibitors of the motor protein; Kinesin-5 (aka KSP, Eg5, KIF11); and Aurora-A, Aurora-B and Polo-like kinases. Microtubule-targeting drugs are among the first line of chemotherapies for a wide spectrum of cancers, but patient responses vary greatly. We still lack understanding of how these drugs achieve a favorable therapeutic index, and why individual patient responses vary. Spindle-targeting drugs have so far shown disappointing results in the clinic, but it is possible that certain patients could benefit if we understand their mechanism of action better. Pre-clinical data from both cell culture and mouse tumor models showed that the cell death response is the most variable point of the drug action. Hence, in this review we focus on current mechanistic understanding of the cell death response to anti-mitotics. We first draw on extensive results from cell culture studies, and then cross-examine them with the more limited data from animal tumor models and the clinic. We end by discussing how cell type variation in cell death response might be harnessed to improve anti-mitotic chemotherapy by better patient stratification, new drug combinations and identification of novel targets for drug development.

Original languageEnglish
Pages (from-to)T83-T96
JournalEndocrine-Related Cancer
Volume24
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Scopus Subject Areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

User-Defined Keywords

  • apoptosis
  • chemotherapy

Fingerprint

Dive into the research topics of 'Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic'. Together they form a unique fingerprint.

Cite this